Skip to content
Pharma Observatory a Scientist.com platform

Gene

PTPRD

PTPRD is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Actionable biomarkers (1), Target-disease associations (502), Vendor sourcing (3), and 3 more evidence types, each linked to its source.

Ensembl ENSG00000153707 UniProt P23468 Matched to Ensembl and UniProt
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Actionable biomarkers Actionable biomarkers 1 Target-disease associations Target-disease associations 502 Vendor sourcing Vendor sourcing 3 Trial-cited literature Trial-cited literature 44 Literature-extracted relations Literature-extracted relations 7 Organizations publishing Organizations publishing 99 Actionable biomarkers Actionable biomarkers 1 Target-disease associations Target-disease associations 502 Vendor sourcing Vendor sourcing 3 Trial-cited literature Trial-cited literature 44 Literature-extracted relations Literature-extracted relations 7 Organizations publishing Organizations publishing 99

Rows recorded per section (log scale)

6 sections measured, none recorded

Cancer actionable (CGI)

Curated as clinically actionable in cancer by the Cancer Genome Interpreter.

Get the PTPRD report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Evidence over time

Share of that year: what fraction of the papers our biomarker dictionary matched in a year mention PTPRD. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.

Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers.

The yearly numbers
PTPRD per year, by evidence type, the most recent 10 years, newest first; the chart covers 1990 to 2023. The share is of the papers our biomarker dictionary matched that year, not of the literature at large, and a blank year is one our matched corpus does not cover at all.
Year Publication mentions Share of that year
2023 7 of 11,460 0.06%
2022 2 of 13,598 0.01%
2021 4 of 15,045 0.03%
2020 8 of 14,459 0.06%
2019 1 of 12,159 0.01%
2018 2 of 11,854 0.02%
2017 1 of 11,595 0.01%
2016 2 of 10,983 0.02%
2015 4 of 11,395 0.04%
2014 3 of 10,367 0.03%

Showing 10 of 34 years.

Start your 14-day trial Email me all 34 years as a PDF

Actionable biomarkers (1)

Shown in this order: fixed catalogue order, not ranked.

Actionable biomarkers
Alteration Drug Response Disease Source
PTPRD oncogenic mutation Igf1r Inhibitors response-associated sarcoma Cancer Genome Interpreter

Target-disease associations (502)

Shown in this order: fixed catalogue order, not ranked.

Target-disease associations
Disease Therapeutic area Source
1-palmitoyl-GPC (16:0) measurement measurement GWAS credible sets
Abnormal blistering of the skin phenotype GWAS credible sets
Abnormal nasolacrimal system morphology phenotype GWAS credible sets
Abnormality of the gastrointestinal tract phenotype GWAS credible sets
Abnormality of the skeletal system phenotype GWAS credible sets

Showing 5 of 502 associations.

Start your 14-day trial Email me the first 50 associations as a PDF

Vendor sourcing (3)

Shown in this order: alphabetical by organization.

Vendor sourcing
Organization Role Tier Evidence Citation
Ambry Genetics (United States) Testing lab / CRO (runs the assay) Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission The c.5537C>T (p.A1846V) alteration is located in exon 45 (coding exon 34) of the PTPRD gene. This alteration results from a C to T substitution at nucleotid... View ClinVar record SCV003536134.2
GeneDx Holdings Corp. Testing lab / CRO (runs the assay) Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission This variant is associated with the following publications: (PMID: 29767709) View ClinVar record SCV001856621.1
Labcorp Holdings Inc. Testing lab / CRO (runs the assay) Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission Variant summary: PTPRD c.(-237+1_-236-1)_(-203+1_-202-1)del is located in the untranslated mRNA region upstream of the initiation codon, hence the impact on ... View ClinVar record SCV007670652.1

Trial-cited literature (44)

Shown in this order: newest first, then most cited.

Trial-cited literature
Publication Journal Year Citations
Genome-wide association meta-analysis identifies 17 loci associated with nonalcoholic fatty liver disease. Nature genetics 2023 159
Pucotenlimab in patients with advanced mismatch repair-deficient or microsatellite instability-high solid tumors: A multicenter phase 2 study. Cell reports. Medicine 2023 8
Genome-wide study of longitudinal brain imaging measures of multiple sclerosis progression across six clinical trials. Scientific reports 2023 8
A phase 1 evaluation of the safety and tolerability of niraparib in combination with everolimus in advanced ovarian and breast cancers. Cancer medicine 2023 7
Contribution of the Epstein-Barr virus to the oncogenesis of mature T-cell lymphoproliferative neoplasms. Frontiers in oncology 2023 6

Showing 5 of 44 papers.

Start your 14-day trial Email me all 44 papers as a PDF

Literature-extracted relations (7)

Shown in this order: chemicals, then diseases.

Literature-extracted relations
Related entity Kind Source relation label Paper Year
Carcinoma, Hepatocellular Disease associate Genome-wide association meta-analysis identifies 17 loci associated with nonalcoholic fatty liver disease. 2023
Non-alcoholic Fatty Liver Disease Disease associate Genome-wide association meta-analysis identifies 17 loci associated with nonalcoholic fatty liver disease. 2023
Lymphoma Disease associate The mutational pattern of primary lymphoma of the central nervous system determined by whole-exome sequencing. 2015
Lymphoma, Large B-Cell, Diffuse Disease associate The mutational pattern of primary lymphoma of the central nervous system determined by whole-exome sequencing. 2015
Neuroblastoma Disease associate Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. 2012

Showing 5 of 7 relation assertions.

Start your 14-day trial Email me all 7 relation assertions as a PDF

Organizations publishing (99)

Shown in this order: most papers first.

Organizations publishing
Organization Type Papers Years
Children's Hospital of Philadelphia Hospital 2 2020
Harvard Medical School Academic 2 2014 to 2017
Heidelberg University Academic 2 2015 to 2021
Helmholtz Association of German Research Centres Government 2 2015 to 2021
Karolinska Institutet Academic 2 2013 to 2021

Showing 5 of 99 organizations.

Start your 14-day trial Email me the first 50 organizations as a PDF

Where PTPRD appears

  • biological_process
  • cancer or benign tumor
  • cardiovascular disease
  • disorder of visual system
  • endocrine system disease
  • gastrointestinal disease
  • genetic, familial or congenital disease
  • hematologic disease
  • immune system disease
  • infectious disease
  • injury, poisoning or other complication
  • integumentary system disease
  • measurement
  • musculoskeletal or connective tissue disease
  • nervous system disease
  • nutritional or metabolic disease
  • phenotype
  • pregnancy or perinatal disease
  • psychiatric disorder
  • respiratory or thoracic disease
  • urinary system disease

480 diseases touched.

Not on this page

Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, assay-provider ledger, trial mentions, protein variant mentions, and human sample screening reference.

Browse all biomarker evidence pages